2-甲基-4-(2-噻吩)-1,3-噻唑 | 21036-67-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-甲基-4-(2-噻吩)-1,3-噻唑
• 中文别名: 2-甲基-4-(2-噻吩基)噻唑,97
• 英文名称: 2-methyl-4-(thiophen-2-yl)thiazole
• 英文别名: 4-(2-Thienyl)-2-methyl-thiazol；2-Methyl-4--thiazol；2-methyl-4-[2]thienyl-thiazole；2-Methyl-4-[2]thienyl-thiazol；2-Methyl-4-(2-thienyl)-1,3-thiazole；2-methyl-4-thiophen-2-yl-1,3-thiazole
• CAS: 21036-67-9
• 化学式: C₈H₇NS₂
• mdl: MFCD01116539
• 分子量: 181.282
• InChiKey: HILMKDNBZMYHDJ-UHFFFAOYSA-N

物化性质

• 熔点：
  61 °C
• 沸点：
  293.0±15.0 °C(Predicted)
• 密度：
  1.266±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  69.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  2-溴-1-(2-THIENYL)-1-ETHANONE 、 硫代乙酰胺 生成 2-甲基-4-(2-噻吩)-1,3-噻唑
  参考文献：
  名称：

  Kempter,G. et al., Zeitschrift fur Chemie, 1968, vol. 8, # 9, p. 339 - 340

  摘要：

  DOI：

文献信息

• [EN] 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS 3H-IMIDAZO[5,1-D][1,2,3,5-TÉTRAZIN-4-ONE 3-SUBSTITUÉS-8-SUBSTITUÉS ET LEUR UTILISATION
  申请人：PHARMINOX LTD

  公开号：WO2010149968A1

  公开（公告）日：2010-12-29

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds of the following formula, wherein -A and -B are as defined herein (collectively referred to herein as 38TM compounds): (1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.

  本发明一般涉及治疗化合物领域，更具体地涉及以下公式的3-取代-8-取代-3H-咪唑[5,1-d][1,2,3,5]四唑-4-酮化合物，其中-A和-B如本文所定义（统称为38TM化合物）：（1）。本发明还涉及包含这种化合物的药物组合物，以及利用这种化合物和组合物在体外和体内抑制细胞增殖，治疗增生性疾病如癌症等的用途，以及制备这种化合物的方法。
• Access to Thiazole via Copper-Catalyzed [3+1+1]-Type Condensation Reaction under Redox-Neutral Conditions
  作者：Xiaodong Tang、Jidan Yang、Zhongzhi Zhu、Meifang Zheng、Wanqing Wu、Huanfeng Jiang

  DOI：10.1021/acs.joc.6b02124

  日期：2016.11.18

  [3+1+1]-type condensation reaction from oximes, anhydrides and potassiumthiocyanate (KSCN) is developed herein. The transformation has good functional group tolerance and various thiazoles were formed smoothly in good to excellent yields under mild reaction conditions. This process involves copper-catalyzed N–O/C–S bond cleavages, activation of vinyl sp2 C–H bond, and C–S/C–N bond formations which are

  本文开发了通过肟，酸酐和硫氰酸钾（KSCN）的铜催化的[3 + 1 + 1]型缩合反应制备噻唑的新策略。该转化具有良好的官能团耐受性，并且在温和的反应条件下以良好至优异的收率顺利形成了各种噻唑。此过程涉及铜催化的N–O / C–S键断裂，乙烯基sp 2 C–H键的活化以及在氧化还原中性条件下的C–S / C–N键形成以及操作简便性。
• 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use
  申请人：Hummersone Marc Geoffery

  公开号：US20120083513A1

  公开（公告）日：2012-04-05

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds of the following formula, wherein -A and —B are as defined herein (collectively referred to herein as 38TM compounds): The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.

  本发明涉及治疗化合物领域，更具体地涉及以下式子的3-取代-8-取代-3H-咪唑[5,1-d][1,2,3,5]四唑-4-酮化合物，其中-A和—B在此定义（统称为38TM化合物）：本发明还涉及包含这种化合物的制药组合物，以及在体内外使用这种化合物和组合物来抑制细胞增殖，治疗增殖性疾病如癌症等，以及制备这种化合物的方法。
• CALCILYTIC COMPOUNDS
  申请人：SmithKline Beecham Corporation

  公开号：EP1951244A2

  公开（公告）日：2008-08-06
• 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE
  申请人：Pharminox Limited

  公开号：EP2445915B1

  公开（公告）日：2016-04-20